Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cloxyquin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 6/20 | 0.96 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.59 |
| ▸ | HSP90AB1 known ✓ | P08238 | 1/20 | 0.59 |
| ▸ | OPRK1 known ✓ | P41145 | 3/20 | 0.58 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.58 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.58 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.58 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.51 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.51 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.51 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.51 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.51 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.51 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.51 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.51 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.51 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.51 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.51 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cloxyquin SCHEMBL29845267 | 1.00 | KDM4E (0.96) | KDM4EHSP90AA1LMNAMAPTMETAP2 | |
| Cloxyquin SCHEMBL29381298 | 0.98 | KDM4E (1.00) | KDM4EHSP90AA1LMNAMAPTMETAP2 | |
| Cloxyquin SCHEMBL115838 | 0.98 | KDM4E (1.00) | KDM4EHSP90AA1LMNAMAPTMETAP2 | |
| Cloxyquin SCHEMBL4292402 | 0.96 | KDM4E (0.96) | KDM4EHSP90AA1LMNAMAPTMETAP2 | |
| Cloxyquin SCHEMBL4302919 | 0.96 | KDM4E (0.96) | KDM4EHSP90AA1LMNAMAPTMETAP2 | |
| Cloxyquin SCHEMBL317736 | 0.96 | KDM4E (0.96) | KDM4EHSP90AA1LMNAMAPTMETAP2 | |
| Cloxyquin SCHEMBL4977328 | 0.96 | KDM4E (0.96) | KDM4EHSP90AA1LMNAMAPTMETAP2 | |
| Cloxyquin SCHEMBL4978867 | 0.96 | KDM4E (0.96) | KDM4EHSP90AA1LMNAMAPTMETAP2 | |
| Cloxyquin SCHEMBL4977294 | 0.96 | KDM4E (0.96) | KDM4EHSP90AA1LMNAMAPTMETAP2 | |
| Cloxyquin SCHEMBL4291941 | 0.96 | KDM4E (0.96) | KDM4EHSP90AA1LMNAMAPTMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108191753-B | Preparation method of 5-chloro-8-hydroxyquinoline | 利尔化学股份有限公司 | 2022-03-15 | — | — | CN | claimed |
| EP-2265677-B1 | CORROSION DETECTION PRODUCT AND METHOD | BATTELLE MEMORIAL INSTITUTE (US) | 2019-05-15 | — | — | EP | claimed |
| CN-108191753-A | A kind of preparation method of 5- chloro-8-hydroxyquinolines | 利尔化学股份有限公司 | 2018-06-22 | — | — | CN | claimed |
| CN-1405155-A | 5-chloro-8-hydroxyquinoline preparation method | LU XIANCHUN (CN) | 2003-03-26 | — | — | CN | claimed |
| US-20240148918-A1 | Loading of Alginate Microspheres | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-05-09 | — | — | US | disclosed |
| EP-4301341-A1 | LOADING OF ALGINATE MICROSPHERES | Board of Regents, The University of Texas System (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117241781-A | Loading of alginate microspheres | 德克萨斯大学系统董事会 | 2023-12-15 | — | — | CN | disclosed |
| CN-115784985-A | Preparation method of halquinol | 郑州原理生物科技有限公司 | 2023-03-14 | — | — | CN | disclosed |
| WO-2022187683-A1 | LOADING OF ALGINATE MICROSPHERES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-09 | — | — | WO | disclosed |
| CN-108191753-B | Preparation method of 5-chloro-8-hydroxyquinoline | 利尔化学股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| WO-2021116712-A1 | FUNCTIONALISED MICROBUBBLE MEDIATED CELL TAGGING | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-06-17 | — | — | WO | disclosed |
| CN-108610288-B | Preparation method and purification method of 5-chloro-8-hydroxyquinoline | 利尔化学股份有限公司 | 2020-11-24 | — | — | CN | disclosed |
| US-7863295-B2 | Treatments for neuropathy | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| EP-2240177-A2 | TREATMENTS FOR NEUROPATHY | Children's Medical Center Corporation (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009102570-A2 | TREATMENTS FOR NEUROPATHY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090203735-A1 | TREATMENTS FOR NEUROPATHY | NIH-DEITR | 2009-08-13 | — | — | US | disclosed |
| CN-1405155-A | 5-chloro-8-hydroxyquinoline preparation method | LU XIANCHUN (CN) | 2003-03-26 | — | — | CN | disclosed |
| US-5032402-A | 3-hydroxy-N-methylpyrrolidone and use as transdermal enhancer | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1991-07-16 | — | — | US | disclosed |
| US-4973708-A | TRANSDERMAL ENHANCER FOR PENETRATION OF DRUGS THROUGH THE SKIN | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1990-11-27 | — | — | US | disclosed |
| EP-0153908-A1 | Process for the preparation of pyridine-2,3-dicarboxylic acid | CIBA-GEIGY AG (CH) | 1985-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203735-A1 | TREATMENTS FOR NEUROPATHY | NGF, BDNF, NTRK2 | HSP90AA1 2449/4885SLC6A2 45/4885HSP90AB1 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.